Printer Friendly

IMMUNOGEN, INC. NAMES CAROL A. GLOFF VICE PRESIDENT OF REGULATORY AFFAIRS

 CAMBRIDGE, Mass., Nov. 22 /PRNewswire/ -- ImmunoGen, Inc. (NASDAQ: IMGN) announced that Carol A. Gloff, Ph.D., has been appointed vice president, Regulatory Affairs. From 1990 to the present, Dr. Gloff was with Alkermes, Inc., most recently as vice president, Regulatory Affairs. At ImmunoGen, she succeeds James A. Taylor, Ph.D., who remains a consultant to the company.
 "Dr. Gloff brings to us considerable expertise and experience in regulatory issues and the drug development process," states Donald J. McCarren, president and chief operating officer. "We are at an important stage in the commercialization of our first products and her skills will be very useful. Our lead product, Oncolysin(R) B, is in a pivotal, Phase III clinical trial in the treatment of non-Hodgkin's lymphoma. Our second product, Oncolysin S, is in Phase II in the treatment of small-cell lung cancer. Over all, we have four products in the clinic for the treatment of different types of cancer."
 McCarren notes that "We are collecting and analyzing data on Oncolysin B that will lead to our first Product License Application for marketing approval, which we expect to file in about two years. We also are preparing to bring our next family of products -- small-drug immunoconjugates for long-term cancer therapy and for the treatment of patients after relapse -- into the clinic. We expect to file our first Investigational New Drug (IND) Application for a small-drug immunoconjugate by the beginning of 1994. Clearly, Dr. Gloff's appointment is an important addition to our senior management team."
 During her tenure at Alkermes, Gloff directed its regulatory affairs, quality assurance and preclinical efforts, including the filing of the company's first three INDs. From 1984 to 1990, she was employed by Triton Biosciences, Inc., first as a Research Scientist and, later, as manager of toxicology/pharmacology. Gloff holds a B.S. from the State University of New York at Buffalo and a Ph.D. in Pharmaceutical Chemistry from the University of California-San Francisco.
 ImmunoGen, Inc. develops innovative therapeutics for the treatment of cancer and immune-mediated diseases. The company produces proprietary toxins and drugs conjugated to highly specific targeting agents which search out and destroy cancer cells. The company's first- generation products, the Oncolysins, are designed for use as post- remission consolidation therapy. The company's small-drug immunoconjugates are intended for use as tumor debulking agents.
 -0- 11/22/93
 /CONTACT: Mark Ratner, director, external communications of ImmunoGen, 617-661-9312/
 (IMGN)


CO: ImmunoGen, Inc. ST: Massachusetts IN: MTC SU: PER

CM-JL -- NE001 -- 6669 11/22/93 08:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 22, 1993
Words:417
Previous Article:FIDELITY NATIONAL FINANCIAL INC. FILES REGISTRATION STATEMENT FOR $160,000,000 PRINCIPAL AMOUNT AT MATURITY OF LIQUID YIELD OPTION NOTES
Next Article:OTIS WINS LANDMARK ELEVATOR CONTRACT IN KUALA LUMPUR
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters